After reviewing the available information, it is recommended that individuals consult with their healthcare provider when considering live vaccines after starting Cosentyx (secukinumab) [1]. Cosentyx, a medication used to treat various conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1][2], may affect the immune system's response to vaccines [1].

According to the Cosentyx prescribing information, "the use of live vaccines should be avoided in patients treated with Cosentyx" [1]. This recommendation is based on the potential impact of Cosentyx on the immune system, which could lead to an altered response to live vaccines [1]. However, the decision to delay live vaccines should be made on a case-by-case basis, considering the individual patient's medical history, the necessity of the vaccine, and the potential risks and benefits [1].

It is important to note that the impact of Cosentyx on vaccine response is not limited to live vaccines. A study published in the Journal of the American Academy of Dermatology found that patients treated with secukinumab (Cosentyx) had reduced antibody responses to both live and inactivated vaccines [3]. Therefore, it is crucial to discuss any vaccination plans with a healthcare provider before starting Cosentyx or during treatment [1][3].

In summary, based on the available information, it is advisable to consult with a healthcare provider regarding live vaccines after starting Cosentyx [1]. The potential impact of Cosentyx on the immune system may affect the response to live vaccines, and the decision to delay vaccination should be made on a case-by-case basis [1].

Sources:

1. Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
2. Cosentyx.com. Novartis. <https://www.cosentyx.com/>
3. Reich K, Blauvelt A, de Wit P, et al. Immunogenicity and safety of varicella-zoster vaccine and tetanus-diphtheria-acellular pertussis vaccine in patients with moderate-to-severe plaque psoriasis treated with secukinumab: a randomized clinical trial. J Am Acad Dermatol. 2017;77(3):455-463.e2. doi:10.1016/j.jaad.2017.03.012
4. DrugPatentWatch.com. Secukinumab (Cosentyx). <https://www.drugpatentwatch.com/drugs/secukinumab>